Physician profile

Muhammad Azharuddin

Medical Oncology · Cleburne, TX

NPI 1669867024

$3,984.44

in general payments reported to CMS, 2019-2025

35 companies · $1,000 in 2025

The $1,000 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,301.47
Education$199.90

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Biotech, INC. $1,140.13 2019-2025 Erleada, Akeega, Rybrevant
Astrazeneca Pharmaceuticals LP $355.01 2022-2025 Calquence, Lynparza, Imfinzi
Pfizer INC. $332.98 2022-2025
Dendreon Pharmaceuticals LLC $313.14 2024-2025 Provenge
Merck Sharp & Dohme LLC $221.67 2022-2025 Keytruda, Welireg, Keytruda Qlex
Beigene USA, INC. $155.29 2021-2024 Brukinsa
Telix Pharmaceuticals $151.28 2024 Illuccix
Tempus Ai, INC $139.45 2024
Regeneron Healthcare Solutions, INC. $130.50 2025 Libtayo
Exelixis INC. $121.69 2023 Cabometyx
E.R. Squibb & Sons, L.L.C. $88.07 2022-2025 Opdivo
Bayer Healthcare Pharmaceuticals INC. $81.95 2024-2025
Spectrum Pharmaceuticals INC. $70.56 2024-2025 Rolvedon
Emd Serono, INC. $61.09 2024-2025
Genzyme Corporation $53.18 2022-2024
Show all 35 companies
CompanyGeneral paymentsYearsTop products
Sumitomo Pharma America, INC. $48.04 2024 Orgovyx
Blue Earth Diagnostics $41.57 2024
Gilead Sciences, INC. $37.24 2024
Novartis Pharmaceuticals Corporation $36.86 2024-2025
Puma Biotechnology, INC. $36.31 2024-2025
Accord Healthcare, INC. $35.06 2022
Rigel Pharmaceuticals, INC. $33.89 2024 Tavalisse, Rezlidhia
Sirtex Medical INC $32.06 2024 Sir-Spheres Microspheres
Amgen INC. $30.63 2019-2024 Prolia, Evenity
Deciphera Pharmaceuticals INC. $29.56 2025 Qinlock, Tgct
Glaxosmithkline, LLC. $29.36 2024 Ojjaara
Takeda Pharmaceuticals U.S.A., INC. $23.86 2025 Ninlaro
Endo USA, INC. $21.87 2024 Aveed, Xiaflex
Stemline Therapeutics INC. $21.68 2025 Orserdu
Abbvie INC. $20.58 2024
Astellas Pharma US INC $20.38 2022
Tolmar, INC. $19.12 2025 Rubraca, Eligard
Pharmaand Gmbh $19.12 2025 Rubraca
Ge Healthcare $15.83 2025
Foundation Medicine, INC. $15.43 2023

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Muhammad Azharuddin

$3,984.44

in general payments reported 2019-2025

Years
2019-2025
Top company
Janssen Biotech, INC.
Context
The $1,000 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).

https://glasscript.com/doctor/5695215/muhammad-azharuddin

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.